Alpha-lipoic acid for diabetic peripheral neuropathy

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of ALA as a disease-modifying agent in DPN, looking at clinical indicators and biomarkers of disease (symptoms, neuropathy scores, ulceration, quality of life, and neurophysiological parameters), and adverse events.